| Name | CYP2D6 |
|---|---|
| Synonyms | CPD 6; Xenobiotic monooxygenase; Microsomal monooxygenase; Flavoprotein linked monooxygenase; CPD6; CYP2D; CYP2D variant; CYP2D6… |
| Name | warfarin |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 20002088 | Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X: Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009 Dec;68(6):928-35. AIMS: To assess the pharmacokinetics (PK) of selective substrates of CYP1A2 CYP2C9 (S-warfarin), CYP2C19 CYP2D6 and CYP3A (midazolam) when administered orally and concurrently as a cocktail relative to the drugs administered alone. |
37(0,1,2,2) | Details |
| 19378397 | Masek V, Anzenbacherova E, Machova M, Brabec V, Anzenbacher P: Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs. 2009 Jun;20(5):305-11. Interestingly, clinically non-significant inhibition was found with the CYP2C9 and CYP2C8 indicating low probability of interactions with, for example, warfarin. Interaction of nine human hepatic cytochromes P450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) with six platinum complexes was studied using pooled human microsomes. |
2(0,0,0,2) | Details |
| 19531695 | Tsao YY, Gugger JJ: Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine. Ann Pharmacother. 2009 Jul;43(7):1366-9. Epub 2009 Jun 16. A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, 1 mg/day, 100 microg/day, 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. |
2(0,0,0,2) | Details |
| 20233183 | Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L: Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol. 2010 Feb;69(2):193-9. METHODS: The activities of seven CYP isoforms (CYP3A4, CYP1A2, CYP2A6, CYP2E1, CYP2D6, CYP2C9, CYP2C8) in human liver microsomes were investigated following co- or preincubation with noscapine. |
1(0,0,0,1) | Details |
| 18855611 | Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, Duan W: Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008 Oct;9(8):738-84. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. |
2(0,0,0,2) | Details |
| 20101557 | Rosskopf D, Meyer zu Schwabedissen HE, Kroemer HK, Siegmund W: [Pharmacogenomics in routine medical care] . Dtsch Med Wochenschr. 2010 Jan;135(4):133-44; quiz 145-6. Epub 2010 Jan 25. Examples include genotyping of CYP2D6 in the context of antidepressant therapy, analysis of TPMT variants for the prediction of mercaptopurine-induced bone marrow depression, VKORC1 and CYP2C9 analyses for a better control of anticoagulant administration and the SLCO1B1 variant in the context of -induced myopathies. |
1(0,0,0,1) | Details |
| 19204416 | Guessous I, Gwinn M, Yu W, Yeh J, Clyne M, Khoury MJ: Trends in pharmacogenomic epidemiology: 2001-2007. Public Health Genomics. 2009;12(3):142-8. Epub 2009 Feb 10. Warfarin was the single most frequently cited drug. Just 4 genes together accounted for nearly one-fifth of all publications: ABCB1, CYP2C9, CYP2C19, and CYP2D6. |
1(0,0,0,1) | Details |
| 19995676 | Limdi NA, Veenstra DL: Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol. 2009 Dec 6. First, warfarin pharmacogenetics, wherein although the validity of the genetic variant dose is established and there is a validity of genetic variant-hemorrhage association, the clinical utility of testing is not clear. Third, the influence of CYP2D6 on tamoxifen efficacy, a model candidate with potential clinical utility but unclear validity. |
1(0,0,0,1) | Details |
| 20147896 | Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A Phenotype-Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clin Pharmacol Ther. 2010 Feb 10. The subjects received oral (p.o.) warfarin + dextromethorphan, and midazolam and (p.o. and intravenous (i.v.)) at baseline, during the first three doses of TPV/r (500 mg/200 mg b.i.d.), and at steady state. |
0(0,0,0,0) | Details |